Cargando…

Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging

Pulmonary infections caused by Pseudomonas aeruginosa (PA) represent the leading cause of pulmonary morbidity in adults with cystic fibrosis (CF). In addition to tobramycin, colistin, and aztreonam, levofloxacin has been approved in Europe to treat PA infections. Nevertheless, no lung deposition dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarz, Carsten, Procaccianti, Claudio, Mignot, Benjamin, Sadafi, Hosein, Schwenck, Nicolas, Murgia, Xabier, Bianco, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708197/ https://www.ncbi.nlm.nih.gov/pubmed/34959333 http://dx.doi.org/10.3390/pharmaceutics13122051

Ejemplares similares

Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis
por: Schwarz, Carsten, et al.
Publicado: (2022)

Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging
por: Usmani, Omar, et al.
Publicado: (2023)

Controlled inhalation improves central and peripheral deposition in cystic fibrosis patients with moderate lung disease
por: Bourke, Crystal, et al.
Publicado: (2022)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Nebulized levofloxacin for chronic Burkholderia cenocepacia pulmonary infection in cystic fibrosis: A case report
por: Dagenais, Renée VE., et al.
Publicado: (2022)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Effects of Levofloxacin, Aztreonam, and Colistin on Enzyme Synthesis by P. aeruginosa Isolated from Cystic Fibrosis Patients
por: Pani, Arianna, et al.
Publicado: (2022)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation
por: Al Hagbani, Turki, et al.
Publicado: (2022)

Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
por: Düesberg, Uta, et al.
Publicado: (2020)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Editorial: Fungal Respiratory Infections in Cystic Fibrosis
por: Papon, Nicolas, et al.
Publicado: (2021)

A Compartment-Based Mathematical Model for Studying Convective Aerosol Transport in Newborns Receiving Nebulized Drugs during Noninvasive Respiratory Support
por: Tarantini, Francesco, et al.
Publicado: (2020)

Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
por: Daddario, Martha K, et al.
Publicado: (2010)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Use of inhaled antibiotics among Danish patients with cystic fibrosis
por: Møller, Rikke, et al.
Publicado: (2022)

Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis
por: Roehmel, Jobst, et al.
Publicado: (2014)

CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
por: Benden, Christian, et al.
Publicado: (2021)

Inhalation with Fucose and Galactose for Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients
por: Hauber, Hans-Peter, et al.
Publicado: (2008)

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
por: Taccetti, Giovanni, et al.
Publicado: (2021)

Biatrial Remodeling in Patients with Cystic Fibrosis
por: Dordevic, Aleksandar, et al.
Publicado: (2019)

The role of respiratory viruses in cystic fibrosis
por: Wat, Dennis, et al.
Publicado: (2008)

Viral respiratory infections in cystic fibrosis
por: van Ewijk, Bart E., et al.
Publicado: (2005)

Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations
por: Usmani, Omar S, et al.
Publicado: (2020)

Rhinovirus C and Respiratory Exacerbations in Children with Cystic Fibrosis
por: de Almeida, Marina B., et al.
Publicado: (2010)

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study
por: Usmani, Omar S., et al.
Publicado: (2021)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
por: AbdulWahab, Atqah, et al.
Publicado: (2017)

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis
por: Chorepsima, Stamatia, et al.
Publicado: (2018)

Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis
por: Blanco-Aparicio, Marina, et al.
Publicado: (2019)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h4cm7dca3tul4d5vmpaofol6u7